3.83 USD
▼-0.18-4.49%
盘后 3.83 -0.13%
2026-09-15
市值
$166.40M
市盈率
—
EPS
-14.44
股息率
—
52 周区间
1.93 – 12.46
成交量
287.17K
Beta
-0.10
目标价
10.33
52W 低 1.9352W 高 12.46
价格走势
公司简介
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.